Financhill
Sell
6

ARVN Quote, Financials, Valuation and Earnings

Last price:
$8.70
Seasonality move :
-15.98%
Day range:
$8.42 - $9.02
52-week range:
$7.91 - $45.77
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.30x
P/B ratio:
1.03x
Volume:
2.2M
Avg. volume:
2.3M
1-year change:
-81.15%
Market cap:
$579.7M
Revenue:
$263.4M
EPS (TTM):
-$2.77

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ARVN
Arvinas
$62.8M -$0.96 71.95% -5.19% $45.26
FBIO
Fortress Biotech
$16.3M -$0.75 -9.13% -41.51% $15.33
HEPA
Hepion Pharmaceuticals
-- -- -- -- --
PFE
Pfizer
$17.3B $0.46 -3.03% 29.69% $31.32
REGN
Regeneron Pharmaceuticals
$3.7B $11.19 9.12% 53% $923.05
ZYME
Zymeworks
$45.2M -$0.09 107.34% -75.24% $21.35
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ARVN
Arvinas
$8.43 $45.26 $579.7M -- $0.00 0% 2.30x
FBIO
Fortress Biotech
$1.66 $15.33 $45.8M -- $0.00 0% 0.32x
HEPA
Hepion Pharmaceuticals
$0.02 -- $244.2K -- $0.00 0% --
PFE
Pfizer
$25.72 $31.32 $145.8B 18.24x $0.43 6.57% 2.30x
REGN
Regeneron Pharmaceuticals
$666.87 $923.05 $72.9B 17.42x $0.88 0.13% 5.40x
ZYME
Zymeworks
$12.25 $21.35 $852.3M -- $0.00 0% 12.18x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ARVN
Arvinas
0.11% 1.554 0.05% 4.58x
FBIO
Fortress Biotech
71.75% 0.988 900.37% 0.99x
HEPA
Hepion Pharmaceuticals
-- 2.743 -- --
PFE
Pfizer
41.92% 0.618 43.87% 0.82x
REGN
Regeneron Pharmaceuticals
6.33% 0.941 2.54% 3.86x
ZYME
Zymeworks
-- 0.851 -- 3.19x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ARVN
Arvinas
-- -$58.2M -32.92% -32.96% -98.31% -$84.4M
FBIO
Fortress Biotech
$9.3M -$22.1M -94.06% -- -166.72% -$20.1M
HEPA
Hepion Pharmaceuticals
-- -$4.5M -- -- -- -$2.5M
PFE
Pfizer
$11.9B $3.2B 5.09% 8.91% 4.1% $5.8B
REGN
Regeneron Pharmaceuticals
$3.2B $1B 14.73% 15.78% 25.56% $995.8M
ZYME
Zymeworks
-- -$22.2M -30.45% -30.45% -71.65% -$41.8M

Arvinas vs. Competitors

  • Which has Higher Returns ARVN or FBIO?

    Fortress Biotech has a net margin of -76.18% compared to Arvinas's net margin of -87.96%. Arvinas's return on equity of -32.96% beat Fortress Biotech's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ARVN
    Arvinas
    -- -$0.63 $562.3M
    FBIO
    Fortress Biotech
    63.87% -$0.76 $41M
  • What do Analysts Say About ARVN or FBIO?

    Arvinas has a consensus price target of $45.26, signalling upside risk potential of 436.93%. On the other hand Fortress Biotech has an analysts' consensus of $15.33 which suggests that it could grow by 823.7%. Given that Fortress Biotech has higher upside potential than Arvinas, analysts believe Fortress Biotech is more attractive than Arvinas.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARVN
    Arvinas
    13 5 0
    FBIO
    Fortress Biotech
    1 0 0
  • Is ARVN or FBIO More Risky?

    Arvinas has a beta of 1.954, which suggesting that the stock is 95.435% more volatile than S&P 500. In comparison Fortress Biotech has a beta of 1.750, suggesting its more volatile than the S&P 500 by 74.992%.

  • Which is a Better Dividend Stock ARVN or FBIO?

    Arvinas has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fortress Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arvinas pays -- of its earnings as a dividend. Fortress Biotech pays out -14.46% of its earnings as a dividend.

  • Which has Better Financial Ratios ARVN or FBIO?

    Arvinas quarterly revenues are $59.2M, which are larger than Fortress Biotech quarterly revenues of $14.6M. Arvinas's net income of -$45.1M is lower than Fortress Biotech's net income of -$12.9M. Notably, Arvinas's price-to-earnings ratio is -- while Fortress Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arvinas is 2.30x versus 0.32x for Fortress Biotech. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARVN
    Arvinas
    2.30x -- $59.2M -$45.1M
    FBIO
    Fortress Biotech
    0.32x -- $14.6M -$12.9M
  • Which has Higher Returns ARVN or HEPA?

    Hepion Pharmaceuticals has a net margin of -76.18% compared to Arvinas's net margin of --. Arvinas's return on equity of -32.96% beat Hepion Pharmaceuticals's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ARVN
    Arvinas
    -- -$0.63 $562.3M
    HEPA
    Hepion Pharmaceuticals
    -- -$0.72 --
  • What do Analysts Say About ARVN or HEPA?

    Arvinas has a consensus price target of $45.26, signalling upside risk potential of 436.93%. On the other hand Hepion Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 130334.78%. Given that Hepion Pharmaceuticals has higher upside potential than Arvinas, analysts believe Hepion Pharmaceuticals is more attractive than Arvinas.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARVN
    Arvinas
    13 5 0
    HEPA
    Hepion Pharmaceuticals
    0 0 0
  • Is ARVN or HEPA More Risky?

    Arvinas has a beta of 1.954, which suggesting that the stock is 95.435% more volatile than S&P 500. In comparison Hepion Pharmaceuticals has a beta of 1.625, suggesting its more volatile than the S&P 500 by 62.537%.

  • Which is a Better Dividend Stock ARVN or HEPA?

    Arvinas has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hepion Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arvinas pays -- of its earnings as a dividend. Hepion Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ARVN or HEPA?

    Arvinas quarterly revenues are $59.2M, which are larger than Hepion Pharmaceuticals quarterly revenues of --. Arvinas's net income of -$45.1M is lower than Hepion Pharmaceuticals's net income of -$4.9M. Notably, Arvinas's price-to-earnings ratio is -- while Hepion Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arvinas is 2.30x versus -- for Hepion Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARVN
    Arvinas
    2.30x -- $59.2M -$45.1M
    HEPA
    Hepion Pharmaceuticals
    -- -- -- -$4.9M
  • Which has Higher Returns ARVN or PFE?

    Pfizer has a net margin of -76.18% compared to Arvinas's net margin of 2.31%. Arvinas's return on equity of -32.96% beat Pfizer's return on equity of 8.91%.

    Company Gross Margin Earnings Per Share Invested Capital
    ARVN
    Arvinas
    -- -$0.63 $562.3M
    PFE
    Pfizer
    66.74% $0.07 $152.1B
  • What do Analysts Say About ARVN or PFE?

    Arvinas has a consensus price target of $45.26, signalling upside risk potential of 436.93%. On the other hand Pfizer has an analysts' consensus of $31.32 which suggests that it could grow by 21.76%. Given that Arvinas has higher upside potential than Pfizer, analysts believe Arvinas is more attractive than Pfizer.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARVN
    Arvinas
    13 5 0
    PFE
    Pfizer
    6 13 1
  • Is ARVN or PFE More Risky?

    Arvinas has a beta of 1.954, which suggesting that the stock is 95.435% more volatile than S&P 500. In comparison Pfizer has a beta of 0.613, suggesting its less volatile than the S&P 500 by 38.72%.

  • Which is a Better Dividend Stock ARVN or PFE?

    Arvinas has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.57% to investors and pays a quarterly dividend of $0.43 per share. Arvinas pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

  • Which has Better Financial Ratios ARVN or PFE?

    Arvinas quarterly revenues are $59.2M, which are smaller than Pfizer quarterly revenues of $17.8B. Arvinas's net income of -$45.1M is lower than Pfizer's net income of $410M. Notably, Arvinas's price-to-earnings ratio is -- while Pfizer's PE ratio is 18.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arvinas is 2.30x versus 2.30x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARVN
    Arvinas
    2.30x -- $59.2M -$45.1M
    PFE
    Pfizer
    2.30x 18.24x $17.8B $410M
  • Which has Higher Returns ARVN or REGN?

    Regeneron Pharmaceuticals has a net margin of -76.18% compared to Arvinas's net margin of 24.22%. Arvinas's return on equity of -32.96% beat Regeneron Pharmaceuticals's return on equity of 15.78%.

    Company Gross Margin Earnings Per Share Invested Capital
    ARVN
    Arvinas
    -- -$0.63 $562.3M
    REGN
    Regeneron Pharmaceuticals
    85.08% $8.06 $31.3B
  • What do Analysts Say About ARVN or REGN?

    Arvinas has a consensus price target of $45.26, signalling upside risk potential of 436.93%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $923.05 which suggests that it could grow by 38.42%. Given that Arvinas has higher upside potential than Regeneron Pharmaceuticals, analysts believe Arvinas is more attractive than Regeneron Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARVN
    Arvinas
    13 5 0
    REGN
    Regeneron Pharmaceuticals
    12 6 0
  • Is ARVN or REGN More Risky?

    Arvinas has a beta of 1.954, which suggesting that the stock is 95.435% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.270, suggesting its less volatile than the S&P 500 by 72.991%.

  • Which is a Better Dividend Stock ARVN or REGN?

    Arvinas has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.13% to investors and pays a quarterly dividend of $0.88 per share. Arvinas pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ARVN or REGN?

    Arvinas quarterly revenues are $59.2M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.8B. Arvinas's net income of -$45.1M is lower than Regeneron Pharmaceuticals's net income of $917.7M. Notably, Arvinas's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 17.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arvinas is 2.30x versus 5.40x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARVN
    Arvinas
    2.30x -- $59.2M -$45.1M
    REGN
    Regeneron Pharmaceuticals
    5.40x 17.42x $3.8B $917.7M
  • Which has Higher Returns ARVN or ZYME?

    Zymeworks has a net margin of -76.18% compared to Arvinas's net margin of -75.75%. Arvinas's return on equity of -32.96% beat Zymeworks's return on equity of -30.45%.

    Company Gross Margin Earnings Per Share Invested Capital
    ARVN
    Arvinas
    -- -$0.63 $562.3M
    ZYME
    Zymeworks
    -- -$0.31 $338.8M
  • What do Analysts Say About ARVN or ZYME?

    Arvinas has a consensus price target of $45.26, signalling upside risk potential of 436.93%. On the other hand Zymeworks has an analysts' consensus of $21.35 which suggests that it could grow by 74.29%. Given that Arvinas has higher upside potential than Zymeworks, analysts believe Arvinas is more attractive than Zymeworks.

    Company Buy Ratings Hold Ratings Sell Ratings
    ARVN
    Arvinas
    13 5 0
    ZYME
    Zymeworks
    7 2 0
  • Is ARVN or ZYME More Risky?

    Arvinas has a beta of 1.954, which suggesting that the stock is 95.435% more volatile than S&P 500. In comparison Zymeworks has a beta of 1.134, suggesting its more volatile than the S&P 500 by 13.422%.

  • Which is a Better Dividend Stock ARVN or ZYME?

    Arvinas has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zymeworks offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arvinas pays -- of its earnings as a dividend. Zymeworks pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ARVN or ZYME?

    Arvinas quarterly revenues are $59.2M, which are larger than Zymeworks quarterly revenues of $31M. Arvinas's net income of -$45.1M is lower than Zymeworks's net income of -$23.5M. Notably, Arvinas's price-to-earnings ratio is -- while Zymeworks's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arvinas is 2.30x versus 12.18x for Zymeworks. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ARVN
    Arvinas
    2.30x -- $59.2M -$45.1M
    ZYME
    Zymeworks
    12.18x -- $31M -$23.5M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is the Market Going to Go Lower?
Is the Market Going to Go Lower?

The last month has been extremely difficult for the stock…

2 Dividend Stocks to Buy in a Recession
2 Dividend Stocks to Buy in a Recession

While many economists and investors initially expected 2025 to be…

Is Ford Stock Undervalued Amid the EV Transition?
Is Ford Stock Undervalued Amid the EV Transition?

There is a lot going on in the electric vehicle…

Stock Ideas

Buy
52
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
56
Is NVDA Stock a Buy?

Market Cap: $3T
P/E Ratio: 41x

Buy
53
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Sell
49
SMTC alert for Mar 17

Semtech [SMTC] is down 0.49% over the past day.

Buy
62
PLPC alert for Mar 17

Preformed Line Products [PLPC] is up 3.8% over the past day.

Sell
50
NUTX alert for Mar 17

Nutex Health [NUTX] is up 4.82% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock